1254733-98-6

Basic information

• Product Name: 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoroacetic acid
• Synonyms: 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoroacetic acid
• CAS NO: 1254733-98-6
• Molecular Weight: 660.663
• Mol File: 1254733-98-6.mol

Chemical Properties

• CAS DataBase Reference: 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoroacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoroacetic acid(1254733-98-6)
• EPA Substance Registry System: 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid trifluoroacetic acid(1254733-98-6)

Safety Data

• Hazardous Substances Data: 1254733-98-6(Hazardous Substances Data)

Upstream product

• 149517-92-0 ethyl 4-bromo-3,5-diethoxybenzoate 
• 1254732-07-4 methyl 4-{8-[(2,6-diethoxy-4'-fluorobiphenyl-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoate trifluoroacetic acid 
• 76-05-1 trifluoroacetic acid 
• 16534-12-6 3,5-dihydroxy-4-bromobenzoic acid 
• 1227405-84-6 4-(chloromethyl)-2,6-diethoxy-4'-fluoro-1,1'-biphenyl 
• 1227405-83-5 (2,6-diethoxy-4'-fluorobiphenyl-4-yl)methanol 
• 1227405-82-4 ethyl 2,6-diethoxy-4'-fluorobiphenyl-4-carboxylate 
• 1254730-81-8 4-{8-[(2,6-diethoxy-4'-fluorobiphenyI-4-yl)methyl]-3-oxo-2,8-diazaspiro[4.5]dec-2-yl}benzoic acid 

Downstream Products

• 1254730-82-9 C₃₂H₃₆FN₃O₄ 

Relevant articles and documents

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition

We report new SSTR5 antagonists with enhanced potency, subtype selectivity, and minimal off-target activities as compared to previously reported compounds. Starting from the reported SSTR5 antagonist 1, we systematically surveyed changes in the central core and head piece while maintaining the diphenyl tail group constant. From this study the azaspirodecanone 10 emerged as a new highly potent and selective SSTR5 antagonist. Compound 10 lowered glucose excursion by 94% in an oral glucose tolerance test (OGTT) in mice following a 3 mg/kg oral dose. The compound increased both total and active circulating incretin hormone GLP-1 levels in mice at a dose of 10 mg/kg. A synergistic effect was also demonstrated when compound 10 was coadministered with a DPP-4 inhibitor, substantially increasing circulating active GLP-1[7-36] amide and insulin in response to a glucose challenge.

SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS

Substituted spirocyclic amines of structural formula I are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.